{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:24:52Z","timestamp":1762457092402,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ebiom.2022.104162","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T07:41:04Z","timestamp":1657870864000},"page":"104162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Schistosomiasis: Basic requirements for the development of a subunit vaccine, using genetic vectors"],"prefix":"10.1016","volume":"82","author":[{"given":"Gul","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2022.104162_bib0001","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.3389\/fimmu.2020.01246","article-title":"Fifteen years of Sm-p80-based vaccine trials in nonhuman primates: antibodies from vaccinated baboons confer protection in vivo and in vitro from Schistosoma mansoni and identification of putative correlative markers of protection","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2022.104162_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.635985","article-title":"Immunological considerations for Schistosoma vaccine development: transitioning to endemic settings","volume":"12","author":"Driciru","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2022.104162_bib0003","first-page":"119","article-title":"Current understanding of immunity against schistosomiasis: impact on vaccine and drug development","volume":"11","author":"Molehin","year":"2020","journal-title":"Res Rep Trop Med"},{"key":"10.1016\/j.ebiom.2022.104162_bib0004","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0925-4439(93)90087-H","article-title":"Characterization of Ca(2+)-dependent neutral protease (calpain) from human blood flukes, Schistosoma mansoni","volume":"1181","author":"Siddiqui","year":"1993","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ebiom.2022.104162_bib0005","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/infdis\/jir545","article-title":"Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic","volume":"204","author":"Ahmad","year":"2011","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104162_bib0006","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"Tatsis","year":"2004","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2022.104162_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2021.198466","article-title":"Adenoviral vector DNA- and SARS-CoV-2 mRNA-based Covid-19 vaccines: possible integration into the human genome - are adenoviral genes expressed in vector-based vaccines?","volume":"302","author":"Doerfler","year":"2021","journal-title":"Virus Res"},{"key":"10.1016\/j.ebiom.2022.104162_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104036","article-title":"A low dose adenovirus vectored vaccine expressing Schistosoma mansoni Cathepsin B protects from intestinal schistosomiasis in mice","volume":"80","author":"Perera","year":"2022","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104162_bib0009","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0166-6851(03)00194-4","article-title":"Functional expression and characterization of Schistosoma mansoni cathepsin B and its trans-activation by an endogenous asparaginyl endopeptidase","volume":"131","author":"Sajid","year":"2003","journal-title":"Mol Biochem Parasitol"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104162_bib0010","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/jps.22267","article-title":"Acceptable levels of endotoxin in vaccine formulations during preclinical research","volume":"100","author":"Brito","year":"2011","journal-title":"J Pharm Sci"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422003437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422003437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:21:17Z","timestamp":1762456877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396422003437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":10,"alternative-id":["S2352396422003437"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104162","relation":{},"ISSN":["2352-3964"],"issn-type":[{"type":"print","value":"2352-3964"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Schistosomiasis: Basic requirements for the development of a subunit vaccine, using genetic vectors","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104162","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104036","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104162"}}